NCT06519032 Development and Evaluation of Rapid Bacterial Species Identification for Acid-Fast Bacilli Smear Using Image Analysis AI
| NCT ID | NCT06519032 |
| Status | Recruiting |
| Phase | — |
| Sponsor | GramEye |
| Condition | Bacterial Infections |
| Study Type | OBSERVATIONAL |
| Enrollment | 10,000 participants |
| Start Date | 2023-09-20 |
| Primary Completion | 2027-03 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 10,000 participants in total. It began in 2023-09-20 with a primary completion date of 2027-03.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this observational study is to develop AI that detects and classifies Acid-Fast Bacilli from microscope images using anonymized and fixed glass slides.
Eligibility Criteria
Inclusion Criteria: * Patients in whom acid-fast bacilli(AFB) smear test was ordered Exclusion Criteria: * No exclusion criteria
Contact & Investigator
Satoshi Kutsuna, PhD,MD
STUDY DIRECTOR
Osaka University Medical Hospital
Frequently Asked Questions
Who can join the NCT06519032 clinical trial?
This trial is open to participants of all sexes, studying Bacterial Infections. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06519032 currently recruiting?
Yes, NCT06519032 is actively recruiting participants. Contact the research team at tatsuya.yamada@grameye.com for enrollment information.
Where is the NCT06519032 trial being conducted?
This trial is being conducted at Suita, Japan.
Who is sponsoring the NCT06519032 clinical trial?
NCT06519032 is sponsored by GramEye. The principal investigator is Satoshi Kutsuna, PhD,MD at Osaka University Medical Hospital. The trial plans to enroll 10,000 participants.